Rare Disease Care a 'Zip Code Lottery,' New Report Reveals

WASHINGTON – February 09, 2026 – For the 30 million Americans living with a rare disease, access to life-sustaining medical care remains a game of chance heavily dependent on geography. A new report released today by the National Organization for Rare Disorders (NORD) reveals a fractured healthcare landscape where a patient's zip code can dictate their ability to access treatment, afford prescriptions, and even obtain essential nutrition.

The 11th annual State Report Card grades all 50 states and Washington, D.C., on policies affecting this vulnerable population, half of whom are children. While the nation collectively earned a “B” grade, reflecting some progress, this average masks profound and persistent disparities that leave families navigating a complex and often unforgiving system.

“We applaud the progress over the past year,” said Pamela K. Gavin, Chief Executive Officer of NORD, in a statement accompanying the report. “But it remains unacceptable that access to life-saving care still depends on where a family lives. No one is immune to acquiring a rare disease. It affects millions of families in every state.”

A Nation Divided by State Lines

The NORD report paints a picture of a nation deeply divided. Only four states—Colorado, Delaware, Maine, and New Jersey—earned an overall 'A' grade for providing a robust framework of patient protections. The vast majority of states lag behind, with 25 earning 'B's and 22 receiving 'C's, underscoring how widely protections vary.

This 'geographic lottery' means that a family in a top-performing state might have access to comprehensive insurance, telehealth services, and affordability programs, while a family in a low-graded state could face insurmountable barriers to the exact same care. These disparities are not abstract policy points; they translate into delayed diagnoses, denied treatments, and devastating financial hardship for families already coping with the immense stress of a rare diagnosis.

The report evaluates states across nine key policy areas, including Medicaid eligibility, insurance safeguards, and prescription affordability. While some states have made strides, the overall picture shows that federal and state policies have yet to create a reliable safety net for all rare disease patients.

Failing on Fundamentals: Nutrition and 'Junk' Insurance

Among the most alarming findings are critical failures in two fundamental areas: medical nutrition and protection from inadequate insurance. According to the report, medical nutrition coverage remains one of the weakest policy areas nationwide. A staggering thirteen states received failing grades, and not a single state earned an 'A' for its policies.

For many rare disease patients, specialized medical foods and formulas are not just dietary supplements; they are the primary treatment required to manage or even survive their condition. For individuals with metabolic disorders like Phenylketonuria (PKU), for example, a specific diet is the only way to prevent severe intellectual disability. Without insurance coverage, these medically necessary formulas can cost families thousands of dollars a month, forcing them to make impossible choices between their health and financial solvency.

Equally concerning is the growing threat of short-term “junk” insurance plans. The report found that 22 states failed to protect patients from these inadequate policies. These plans are exempt from Affordable Care Act (ACA) protections, meaning they can legally deny coverage for pre-existing conditions—a devastating reality for anyone with a diagnosed rare disease. They can also exclude essential benefits like prescription drugs and impose caps on coverage.

The risk to patients was magnified in August 2025 when federal agencies deprioritized enforcement against these plans, effectively shifting the primary responsibility for regulation to the states. The NORD report reveals that nearly half of the states have not risen to this challenge, leaving their residents exposed to policies that offer a false sense of security until a medical crisis strikes.

The Growing Power of the Patient Voice

As federal oversight wanes in some areas, the report highlights the increasing importance of state-level advocacy and the power of the patient voice. A key mechanism for this is the creation of Rare Disease Advisory Councils (RDACs)—formal bodies that provide patients, caregivers, and experts a seat at the table to help shape state healthcare policy.

According to NORD, 19 states still lack an RDAC, limiting direct patient input at a time when state decisions are more critical than ever. However, momentum is building. Since launching its Project RDAC initiative in 2020, NORD has helped establish 25 of the 33 councils that now exist nationwide.

In 2025 alone, four states—Vermont, Oklahoma, Hawaii, and Pennsylvania—introduced legislation to establish new councils. “Every Vermonter deserves to be seen, heard, and supported, especially those living with rare diseases who too often fall through the cracks of our healthcare system,” said Rep. Mary-Katherine Stone (D-VT) regarding her state's bill. “The Rare Disease Advisory Council is how we start making that commitment real.”

The presence of these councils in four of the five most populous states (California, Florida, New York, and Pennsylvania) demonstrates their growing acceptance, while the absence of one in Texas highlights a significant gap in a major state.

Bright Spots in a Challenging Landscape

Despite the significant challenges, the report does identify areas of meaningful progress. The expansion of telehealth stands out as a major victory, with 43 states earning passing grades. For rare disease patients, who often must consult with a handful of specialists located across the country, telehealth is a lifeline. It breaks down geographic barriers, reduces travel costs and burdens, and improves access to the expert care that is often essential for managing their conditions.

Improvements in prescription drug affordability in several states also contributed to the nation's overall 'B' grade, suggesting that some policy efforts to control out-of-pocket costs are taking hold. Yet, these bright spots are cast against the shadow of the larger, systemic inconsistencies. While progress is being made, it is incremental and uneven, leaving millions of the nation's most vulnerable patients navigating a system where their health is determined less by medical need and more by their state of residence.